Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Cyramza Summary of Product Characteristics (SmPC)

Cyramza® (ramucirumab): Extravasation

If extravasation occurs or is suspected, follow your local procedures for managing nonvesicant extravasation.

Detailed Information

Ramucirumab is a nonvesicant as it is an antibody in a neutral formulation that is a specific receptor antagonist. No dedicated extravasation studies were conducted in animals. However, local tolerance was investigated in 2 repeat-dose toxicity evaluations in cynomolgus monkeys by clinical observations and as part of the histopathological evaluations. Intravenous administration of ramucirumab was well tolerated at all dose levels. Mild, local injection-site reactions were observed and consisted of mononuclear and/or polymorphonuclear cells in the perivascular areas.1

If extravasation occurs or is suspected, follow your local procedures for managing nonvesicant extravasation.

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: August 07, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question